This study is for people with advanced or metastatic solid tumors, which means the cancer is large or has spread. The tumors must have a marker called HER2. The study is testing a new drug called disitamab vedotin (DV). DV is an antibody-drug conjugate (ADC), a special medicine that finds and attacks cancer cells. Participants will get DV every two weeks to see if it helps treat their tumors and to check for any side effects, which are unwanted changes in the body.

• Duration: Participants receive treatment every 2 weeks.
• Participation Requirements: Includes having a HER2-positive tumor and certain types of cancer such as head and neck, lung, ovarian, or endometrial cancer.
• Risks: Possible side effects vary and include any reaction the body may have to the drug.

To join, participants must meet specific criteria, such as having previously received certain treatments. Some cannot join if they have received specific prior treatments or have certain health conditions. This study aims to find out if DV can help treat different types of cancer connected to the HER2 marker.